SPEAKERS



WHERE ARE WE HEADED? IMPLICATIONS OF A NEW CONGRESS


David Wasserman will discuss the outcomes of the 2018 midterms, how the new Congress is affecting change, and the expected impact on businesses from a policy and regulation perspective. Drawing on his extensive research on cultural, demographic, and voting patterns, Wasserman assesses how we arrived at this critical moment in politics and where the top policy debates are headed.

David Wasserman
House Editor, The Cook Political Report

Click here for full bio

USDA FSIS REGULATORY CONSIDERATIONS AND LABELING UPDATE


The development of new products and labeling claims are subject to FDA and FSIS regulatory oversight. This session will provide an overview of FSIS regulatory considerations including jurisdiction, special claims, prior label approval as well as the coordination of regulatory and policy development with other government agencies.

Jeffrey W. Canavan, MPA, RD
Labeling and Program Delivery Staff, Food Safety and Inspection Service, USDA

Click here for full bio

EXPORT CERTIFICATION FROM FDA/CFSAN: BETTER, FASTER, STRONGER


Kate Meck from FDA/CFSAN will explain the recent changes to their export certification program, including the availability of two new types of export certificates. She will describe how the new certificates contain stronger attestations and allow for the inclusion of additional data elements and information, providing increased flexibility for exporters to meet importing country requirements.

Kate Meck
International Policy Analyst, International Affairs Staff, Center for Food Safety and Applied Nutrition (CFSAN)
U.S. Food and Drug Administration (FDA)

Click here for full bio

FUNDING FDA: THE SHUTDOWN IS OVER, BUT OPPORTUNITIES AND THREATS STILL ABOUND


The breadth of FDA’s responsibilities was never clearer than in the recent shutdown. Americans had to consider, many for the first time, whether they wanted additional risk in their supply of food, drugs, devices, cosmetics, personal care products, pet food, etc. However, the story starts much earlier, a decade ago, when a multi-stakeholder coalition came together to advocate for additional resources for all parts of the FDA. The agency’s appropriated resources have doubled since then. Still, the agency could definitely do more, if it had more resource. This presentation will delineate the sources of FDA funding, the problems the agency has had to overcome to build programs, and the future of agency funding, both short and long-term.

Steven Grossman
Deputy Executive Director
Alliance for a Stronger FDA

Click here for full bio